TFA Therapeutics, Inc.
RAJAF · OTCMCIK 1885680fmd_0KZV3XJWYKK106MJZMDXTFP75KManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2021 to Dec 31, 2025, 7 periods
Latest annual · FY2025
Millions- Total revenues
- 1
- Gross profit
- 1
- Operating income
- (0)
- Net income
- (0)
- Free cash flow
- (0)
Latest quarter · Q4 FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- 0
- Net income
- 1
- Free cash flow
- (0)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +185.9%
TFA Therapeutics, Inc. (RAJAF) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1.2 million | $1.3 million | -0.6% | 20-F 2026-05-15 · proof |
| Gross profit | $760,741 | $906,480 | -16.1% | 20-F 2026-05-15 · proof |
| Operating income | -$141,128 | -$183,913 | 20-F 2026-05-15 · proof | |
| Net income | -$154,822 | -$226,258 | 20-F 2026-05-15 · proof | |
| Cash from operating activities | -$35,845 | $312,006 | -111.5% | 20-F 2026-05-15 · proof |
| Total assets | $4.7 million | $4.6 million | +0.7% | 20-F 2026-05-15 · proof |
| Total liabilities | $5.2 million | $5 million | +3.9% | 20-F 2026-05-15 · proof |
| Cash and cash equivalents | $3,199 | $37,284 | -91.4% | 20-F 2026-05-15 · proof |
- What was TFA Therapeutics, Inc. (RAJAF)'s revenue in fiscal 2025?
- TFA Therapeutics, Inc. (RAJAF) reported revenue of $1.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $1.3 million the year before (-0.6%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was TFA Therapeutics, Inc. (RAJAF)'s gross profit in fiscal 2025?
- TFA Therapeutics, Inc. (RAJAF) reported gross profit of $760,741 for fiscal 2025 (the year ended Dec 31, 2025), against $906,480 the year before (-16.1%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was TFA Therapeutics, Inc. (RAJAF)'s operating income in fiscal 2025?
- TFA Therapeutics, Inc. (RAJAF) reported operating income of -$141,128 for fiscal 2025 (the year ended Dec 31, 2025), against -$183,913 the year before. Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was TFA Therapeutics, Inc. (RAJAF)'s net income in fiscal 2025?
- TFA Therapeutics, Inc. (RAJAF) reported net income of -$154,822 for fiscal 2025 (the year ended Dec 31, 2025), against -$226,258 the year before. Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What was TFA Therapeutics, Inc. (RAJAF)'s cash from operating activities in fiscal 2025?
- TFA Therapeutics, Inc. (RAJAF) reported cash from operating activities of -$35,845 for fiscal 2025 (the year ended Dec 31, 2025), against $312,006 the year before (-111.5%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What are TFA Therapeutics, Inc. (RAJAF)'s total assets?
- As of Dec 31, 2025, TFA Therapeutics, Inc. (RAJAF) reported total assets of $4.7 million, against $4.6 million a year earlier (+0.7%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What are TFA Therapeutics, Inc. (RAJAF)'s total liabilities?
- As of Dec 31, 2025, TFA Therapeutics, Inc. (RAJAF) reported total liabilities of $5.2 million, against $5 million a year earlier (+3.9%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
- What are TFA Therapeutics, Inc. (RAJAF)'s cash and cash equivalents?
- As of Dec 31, 2025, TFA Therapeutics, Inc. (RAJAF) reported cash and cash equivalents of $3,199, against $37,284 a year earlier (-91.4%). Source: the 20-F filed with the SEC on May 15, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RAJAF&period_type=annual&limit=5"Information only, not investment advice.